Oxford-based Greywolf Therapeutics has reported early clinical activity for its first-in-class oral ERAP1 inhibitor GRWD5769 in combination with the anti-PD-1 antibody cemiplimab across six solid tumour types, presenting Phase 1b data from the EMITT-1 trial at the 2026 ASCO Annual Meeting.
Immatics has published a series of updates on its PRAME pipeline, using the American Society for Clinical Oncology (ASCO) Annual Meeting to share data on its lead candidate and next-generation program.
Swiss ophthalmology biotech Oculis has suffered a major setback for its most advanced ophthalmology programme after two pivotal Phase III trials of OCS-01 eye drops in diabetic macular edema failed to meet their primary endpoint.
French pharmaceutical group Servier has agreed to acquire sevasemten and the muscular dystrophy business built around it from US biotech Edgewise Therapeutics Inc. in a transaction worth up to US$2.65bn, giving the Paris-based company a late-stage entry into Becker and Duchenne muscular dystrophy.
T-CURX acquires Pantherna: does this mark the start of a new race for the next generation of CAR-T therapies? The Würzburg- and Munich-based CAR-T company T-CURX is acquiring the Berlin-based mRNA and LNP company Pantherna Therapeutics. Financial details of the transaction were not disclosed. Pantherna is to continue operating in Hennigsdorf as a wholly owned subsidiary.
Erik Lundgren assumed his role as the new CEO of Immunic. He succeeds Dr Daniel Vitt, who will continue to oversee the biotech company’s scientific strategy.
ROGER HARRIS/SCIENCE PHOTO LIBRA-stock.adobe.com
Immunic AG